These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37353655)

  • 1. Modelling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies.
    Karnati P; Murthy A; Gundeti M; Ahmed T
    AAPS J; 2023 Jun; 25(4):63. PubMed ID: 37353655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.
    Kollipara S; Martins FS; Sanghavi M; Santos GML; Saini A; Ahmed T
    J Pharm Sci; 2024 Feb; 113(2):345-358. PubMed ID: 38043684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
    Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
    Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions.
    Boddu R; Kollipara S; Vijaywargi G; Ahmed T
    Xenobiotica; 2023 Apr; 53(4):260-278. PubMed ID: 37471259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products.
    Subhani S; Kim C; Muniz P; Rodriguez M; van Os S; Suarez E; Cristofoletti R; Schmidt S; Vozmediano V
    Eur J Pharm Biopharm; 2022 Jul; 176():87-94. PubMed ID: 35598768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained-release formulations.
    Severino Martins F; Borges L; Oliveira do Couto R; Schaller S; de Freitas O
    Biopharm Drug Dispos; 2023 Aug; 44(4):335-343. PubMed ID: 37649136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.
    Tsakalozou E; Mohamed MF; Polak S; Heimbach T
    AAPS J; 2023 Oct; 25(6):96. PubMed ID: 37783902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.
    Zhang F; Jia R; Gao H; Wu X; Liu B; Wang H
    Clin Pharmacokinet; 2021 Nov; 60(11):1373-1385. PubMed ID: 34191255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
    Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
    J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of fasted and fed bioequivalence for immediate release drug products using physiologically based biopharmaceutics modeling (PBBM).
    Jereb R; Kristl A; Mitra A
    Eur J Pharm Sci; 2020 Dec; 155():105554. PubMed ID: 32946959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence Common Deficiencies in Generic Products Submitted for Registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Sep; 56(5):822-838. PubMed ID: 35896784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products-a Meeting Report.
    Tsakalozou E; Fang L; Bi Y; van den Heuvel M; Ahmed T; Tsang YC; Lionberger R; Rostami-Hodjegan A; Zhao L
    AAPS J; 2024 Jan; 26(1):14. PubMed ID: 38200397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report.
    Al Shoyaib A; Riedmaier AE; Kumar A; Roy P; Parrott NJ; Fang L; Tampal N; Yang Y; Jereb R; Zhao L; Wu F
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):610-618. PubMed ID: 36597353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report.
    Wu F; Mousa Y; Raines K; Bode C; Tsang YC; Cristofoletti R; Zhang H; Heimbach T; Fang L; Kesisoglou F; Mitra A; Polli J; Kim MJ; Fan J; Zolnik BS; Sun D; Zhang Y; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):585-597. PubMed ID: 36530026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-Based Pharmacokinetic Modeling to Support Determination of Bioequivalence for Dermatological Drug Products: Scientific and Regulatory Considerations.
    Tsakalozou E; Alam K; Babiskin A; Zhao L
    Clin Pharmacol Ther; 2022 May; 111(5):1036-1049. PubMed ID: 34231211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.